Netherlands' ProQR Q3 revenue rises, beats analyst estimates

Overview

• Netherlands RNA therapy developer's Q3 revenue rose and beat analyst expectations

• Company posted Q3 net loss of €12.4 mln, or €0.09 per share

• Quarter-end cash and equivalents at €103 mln, supporting runway into mid-2028

Outlook

• ProQR expects initial AX-0811 Phase 1 data in early January 2027

• Company to present full AX-0810 Phase 1 dataset and new AX-0811 preclinical data in December 2026

• Multiple clinical milestones expected in H1 2027, including pediatric biliary atresia and MPS I Hurler syndrome trials

Result Drivers

• CLINICAL DEVELOPMENT PROGRESS - Co attributed pipeline expansion and clinical trial advancement, especially in NTCP programs, as key operational focus areas

• HIGHER R&D SPENDING - Increased research and development costs contributed to the quarterly net loss

• AI AND DATA INITIATIVES - Co emphasized strengthening AI capabilities through new executive appointments and board advisory roles

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for ProQR Therapeutics NV is $8.00, about 534.9% above its November 11 closing price of $1.26

Reuters Recommended Reads

• Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations

• Nov 10 - Germany's Immatics Q3 revenue misses estimates, net loss widens on higher spending

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)